Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Prescription Drug User Fee Amendments

Prescription Drug User Fee Amendments Home
          For Industry
          FDA User Fee Programs
          Prescription Drug User Fee Amendments
          Enhancing Benefit-Risk Assessment in Regulatory Decision-MakingPrescription Drug User Fee Amendments Enhancing Benefit-Risk Assessment in Regulatory Decision-Making
  
  	
    Share
    Post
    Linkedin

    Email
    PrintBenefit-risk assessment is an integral part of FDA’s regulatory review of marketing applications for new drugs and biologics. These assessments capture the Agency’s evidence, uncertainties, and reasoning used to arrive at its final determination for specific regulatory decisions. Additionally, they serve as a tool for communicating this information to those who wish to better understand FDA’s thinking.

Beginning with commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), the Agency has identified and implemented enhancements with the goal of increasing the clarity, transparency, and consistency of FDA’s benefit-risk assessments in human drug review. With passage of the 21st Century Cures Act, FDA also has an imperative to consider how relevant patient experience data and related information can be incorporated into the structured benefit-risk assessment framework to inform regulatory decision-making.

As part of its commitments under PDUFA VI and requirements under 21st Century Cures, FDA has developed a draft guidance for industry on benefit-risk assessment for new drug and biological products. The intent of this guidance, when finalized, is to clarify for drug  sponsors and other stakeholders how considerations about a drug’s benefits, risks, and risk management options factor into certain premarket and postmarket regulatory decisions that the Agency makes about new drug applications submitted under section 505(c) of the Federal Food, Drug, and Cosmetic Act as well as biologics license applications submitted under section 351(a) of the Public Health Service Act.

The guidance is available here: PDUFA VI Benefit-Risk Guidance
	The public docket is available here: Public Docket
	A snapshot of the guidance and accompanying podcast is available here: Snapshot and PodcastAs part of our PDUFA VI commitments, FDA also committed to convening and/or participating in at least one meeting to gather industry, patient, researcher, and other stakeholder input on applying FDA’s Benefit-Risk Framework throughout the human drug development and post-marketing lifecycle and best approaches to communicating FDA’s benefit-risk assessment. Input from this meeting supported development of the draft guidance on benefit-risk assessment. This meeting was convened on May 16, 2019, by the Duke-Margolis Center for Health Policy.

The federal register notice which announced this meeting is available here: Federal Register Notice
	More information about the meeting, including a meeting recording, is available on the Duke-Margolis meeting page.Additional information related to FDA’s implementation and ongoing enhancement of benefit-risk assessment in human drug and biologic regulatory decision-making is available below.

PDUFA VI

Draft PDUFA VI Implementation Plan: Benefit-Risk Assessment in Drug Regulatory Decision-MakingPDUFA V

Draft PDUFA V Implementation Plan: Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making
	PDUFA V Benefit-Risk Plan; Request for Comments
	Public Workshops on Benefit-Risk ConsiderationsResources For You

PDUFA V: Fiscal Years 2013 - 2017
	PDUFA VI: Fiscal Years 2018 - 2022
	Condition-Specific Meeting Reports and Other Information Related to Patients' Experience

                                                                                  Content current as of:
      07/15/2022
              
              
Regulated Product(s)
		 DrugsPrescription Drug User Fee Amendments
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop